NP / PA
Central Ky Urgent Care Center INC
Central Ky Urgent Care Center INC was paid $1.84M by Medicaid between Jan 2018 and Nov 2024, across 25 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 33% of everything it billed.
33Billing provider infoCENTRAL KY URGENT CARE CENTER INC
RICHMOND, KY 40475
RICHMOND, KY 40475
33aNPI1023535796assigned 08/24/2017
33bProvider typePhysician Assistant
28Total paid$1.84M
24GClaims76,998
24DCodes billed25
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Physician Assistant providers in Kentucky
Rank by total paid#29 of 214
Median peer was paid$134K
This provider vs. median14×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,988 | $97K | |
| 2019 | 8,470 | $212K | |
| 2020 | 10,279 | $199K | |
| 2021 | 13,036 | $249K | |
| 2022 | 15,022 | $409K | |
| 2023 | 14,989 | $426K | |
| 2024incomplete | 10,214 | $247K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 33% | 21,088 | 18,910 | $614K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 16% | 5,180 | 4,687 | $292K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 11% | 14,905 | 6,344 | $211K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 8.5% | 3,380 | 3,108 | $156K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 6.3% | 4,526 | 3,498 | $116K |
| 80305 | 5.2% | 10,788 | 4,106 | $96K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 4.0% | 6,238 | 5,846 | $73K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 3.5% | 777 | 696 | $64K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 2.3% | 1,217 | 1,031 | $41K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.0% | 2,136 | 1,923 | $37K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 1.8% | 1,113 | 1,052 | $34K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.2% | 277 | 253 | $22K |
13 more codes
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.1% | 1,525 | $21K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.1% | 96 | $20K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.0% | 941 | $19K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 239 | $7K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 76 | $6K |
| 99201 | <1% | 325 | $5K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 123 | $4K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,029 | $920.23 |
| 87807 | <1% | 73 | $766.64 | |
| 81003 | <1% | 853 | $170.99 | |
| J1741 | Injection, ibuprofen, 100 mg | <1% | 57 | $58.50 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 18 | $41.00 |
| J3490 | Unclassified drugs | <1% | 18 | $0.81 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGHIMIRE, BIJAYA (PRESIDENT)